SCLC

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 09/07/2020)
 

Non-metastatic stage

Currently no trials

Metastatic stage

1st line

Currently no trials

2nd line
RESILIENT (Ipsen)
A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy.

3th line
Currently no trials